Comparison of Efficacy and Safety of Rosuvastatin, Atorvastatin and Pravastatin among Dyslipidemic Diabetic Patients

Table 3

Safety comparison on hepatic, renal, and muscular functions: adverse events after 2 years of statin use.

Variables	Ator; 10 mg; 𝑛=50 (%)	Ator; 20 mg; 𝑛=50 (%)	Ator; 40 mg; 𝑛=50 (%)	Ros; 10 mg; 𝑛=50 (%)	Ros; 20 mg; 𝑛=50 (%)	Prav; 20 mg; 𝑛=50 (%)	Prav; 40 mg; 𝑛=50 (%)
Hepatic function
ALT > 3 × ULN	0	0	0	0	0	0	0
Renal function
Normal; (eGFR ≥ 90 mL/min/1.73 m^2)	38 (76.0)	32 (64.0)	30 (60.0)	37 (74.0)	30 (60.0)	34 (68.0)	30 (60.0)
Mild; (eGFR 60–89 mL/min/1.73 m^2)	10 (20.0)	14 (28.0)	16 (32.0)	9 (18.0)	14 (28.0)	11 (22.0)	15 (30.0)
Moderate; (eGFR 30–59 mL/min/1.73 m^2)	2 (4.0)	4 (8.0)	5 (10.0)	4 (8.0)	6 (12.0)	5 (10.0)	4 (8.0)
Severe; (eGFR 15–29 mL/min/1.73 m^2)	0	0	0	0	0	0	0
Kidney failure; (eGFR < 15 mL/min/1.73 m^2)	0	0	0	0	0	0	0
Microalbuminuria
At baseline without ACE inhibitors; and/or ARBs	2 (4.0)	2 (4.0)	0	1 (2.0)	1 (2.0)	2 (4.0)	4 (8.0)
At 2 years after without ACE inhibitors; and/or ARBs	2 (4.0)	2 (4.0)	0	1 (2.0)	1 (2.0)	1 (2.0)	1 (2.0)
At baseline with ACE inhibitors; and/or ARBs	8 (16.0)	17 (34.0)	11 (22.0)	15 (30.0)	13 (26.0)	12 (24.0)	17 (34.0)
At 2 years after with ACE inhibitors; and/or ARBs	8 (16.0)	20 (40.0)	14 (28.0)	17 (34.0)	14 (28.0)	15 (30.0)	18 (36.0)
Macroalbuminuria	0	0	0	0	0	0	0
CK level
>10 × ULN	0	0	0	0	0	0	0